Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (OP: ENSCW )

0.0250 UNCHANGED
Streaming Delayed Price Updated: 10:14 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences Inc

< Previous 1 2 Next >
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Via ACCESSWIRE
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Via ACCESSWIRE
Ensysce Biosciences Presenting at Upcoming Meetings
Via ACCESSWIRE
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Via ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
Via ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Via ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Via ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Via ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Via ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Via ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Via ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
Via ACCESSWIRE
Ensysce Biosciences to Participate in Upcoming Industry Events
Via ACCESSWIRE
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
Via ACCESSWIRE
Ensysce Biosciences Issues 2024 Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
Via ACCESSWIRE
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
Via ACCESSWIRE
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
Via ACCESSWIRE
Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
Via ACCESSWIRE
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
Via ACCESSWIRE
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
Via ACCESSWIRE
Ensysce Biosciences Issues 2023 Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2022 Financial Results
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.